
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ST101
Therapeutic Area : Oncology
Study Phase : Undisclosed
Recipient : ProBioGen
Deal Size : Undisclosed
Deal Type : Collaboration
ProbioGen, Spica Collaborate on GlymaxX-Enhanced CLD for ST101 Clinical Development
Details : The collaboration aims to advance oncology research through the development of ST101, an unconjugated antibody targeting CD163.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
December 11, 2025
Lead Product(s) : ST101
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Recipient : ProBioGen
Deal Size : Undisclosed
Deal Type : Collaboration
